Home » Business » AEX wins the finish line on Prinsjesdag | Financial

AEX wins the finish line on Prinsjesdag | Financial

After a flat start, the AEX index took a tailwind and ended 0.6% higher at 555.95 points. The AMX rose 0.8% to 816.96 points.

Elsewhere in Europe, the stock market indicators also turned green. The British FTSE 100, the French CAC and the German DAX advanced by up to 1%.

In the morning, favorable macro news came from Germany. Investors’ confidence in the prospects for their own economy has become stronger this month than anticipated. The macro figures from China were also better than expected. Jos Versteeg, analyst at InsingerGilissen, emphasizes that the growth of retail sales in the Asian country can be called particularly encouraging. “That was the first time since the outbreak of the corona pandemic.”

We also have to wait for the American interest rate decision that will be released tomorrow evening. According to Philip Marey, economist at Rabobank, the so-called dot plot will be in the spotlight, which gives an indication of the outlook for interest rates in the medium term. “We are taking into account in our forecast that the Fed will not increase interest rates again until the end of 2024. Powell will also discuss in the explanation the previously announced flexibilisation of the inflation target. ”

“Turbulence on the way”

Marey foresees that the equity markets will face the necessary turbulence in the fourth quarter. He points out that, especially after the presidential elections in the US, there may be a period of unrest. “Due to the enormous polarization in American politics, it is not inconceivable that the presidential candidates will dispute the result, especially because there is a lot of voting by post. A possible second outbreak of the coronavirus in the US during the flu season is also a source of uncertainty. In addition, Trump can still wield the blunt ax towards China and there is a chance that the Republican and Democrats will not get out at all with the new fiscal stimulus. ”

Versteeg still looks at the stock market with a positive outlook. “There is a bit more volatility in the market, but you can see investors shrugging off the dust of the tech correction last week. Tech funds are expected to continue to pull the cart because of the good profit growth because they still benefit from the massive working from home due to the corona crisis. ”

Shell aan kop

Meal delivery service went to the Dutch main funds Just Eat Takeaway 0.9% ahead, following a buy recommendation from Citi. The American bank has a target price of € 138.

Heavyweight Shell posted a gain of 1.5%, supported by a recovery in oil prices. The International Energy Agency (IEA) foresees that the recovery of the oil market in the second half of this year will be less strong than previously thought. Unilever also attacked 1.1% in flavor and thickness.

ABN Amro lost 2.8% after the nice plus on Monday. ING fell 1.2%. Swiss banks UBS, where former ING CEO Ralph Hamers will soon take over the helm, and Credit Suisse have reportedly started an investigation into a possible merger.

The medium-sized funds shone Eurocommercial Properties with a price jump of 6.8% after JPMorgan removed the real estate company from the sales list.

Signify Also on the rise, up 3.6%, Goldman Sachs has put the lighting company on its favorites list.

SBM Offshore gained 5% after a strong revival around lunch. Investors welcomed the news that the oil industry service provider is in exclusive negotiations with Brazilian oil giant Petrobras to supply a floating production platform to produce gas and oil.

Vopak on the other hand lost 0.4%. On Monday, investors had reacted cautiously positively to a takeover of terminals in the US.

Smallcap Forfarmers won 3.6%, in response to the announcement of its financial targets for the next five years. The animal feed company wants to continue to grow in Europe and pay more dividends.

Kiadis Pharma shot up 10.7% in the local market, thanks to the receipt of a $ 9.5 million grant from the US for the further development of a corona drug. The biotechnology company had already hinted at this on Monday, when it received approval from the FDA to start a clinical trial into the treatment of Covid-19. Investment bank KBC saw reason to increase its target price to € 2.80, but stuck to its holding advice.

Would you like to receive the DFT Newsletter automatically by email every morning from now on? Then you can sign up here for free.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.